Research Publications.

BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib

resistant melanoma:

Preformulation studies, formulation development and in vitro evaluation

Drishti Rathod, Yige Fu, Ketan Patel 

EphA2-Receptor Targeted PEGylated Nanoliposomes

for the Treatment of BRAF V600E Mutated Parent-and Vemurafenib-Resistant Melanoma

Yige Fu, Drishti Rathod, Ehab M. Abo-Ali, Vikas Dukhande, Ketan Patel

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated

Nanoliposomes

for the treatment of vemurafenib-resistant melanoma

Yige Fu, Drishti Rathod, Ketan Patel